Scientists at The Institute of Cancer Research, London, found that combining two separate molecularly targeted therapies could stop processes driving growth in a cancer called rhabdomyosarcoma, a major cause of cancer death in children. The drugs, called AZD8055 and AZD6244, block two different signalling pathways involved in cancer growth — acting like road-blocks on two separate routes that cancers could otherwise use to evade treatment. The study, published in Clinical Cancer Research, was funded by the NIHR Biomedical Research Centre for Cancer at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR), with additional funding from Cancer Research UK, The Royal Marsden Hospital Charitable Fund and the Chris Lucas Trust. Rhabdomyosarcoma tumours can form anywhere in the body and resemble primitive muscle tissue…